Fatty acid synthase inhibitor reduces liver fat, markers of liver injury in NASH

TVB-2640, a fatty acid synthase inhibitor, significantly reduced liver fat and serum biomarkers of liver injury, fibrosis and inflammation in patients with nonalcoholic steatohepatitis according to research presented at The Digital International Liver Congress.“Once daily, oral tablet of TVB-2640 appeared to be well-tolerated and had a good safety profile,” Rohit LoombaMD, MHSc, from the division of gastroenterology at the University of California at San Diego, said during his presentation. “[We] believe that these data provide justification for examining the efficacy ofRead More

Share on facebook
Share on twitter
Share on linkedin